We are a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics

Our proprietary extended release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates very often administered post surgically.

  • PRF-110

    Viscous clear oil-based solution that is instilled directly into the surgical wound

    Providing localized and extended post-operative analgesia. Its physical characteristics and composition are key to it being well-tolerated and its ease of use.

  • Market

    The currently marketed non-opiate extended relief post-surgical topical products are based on a complicated formulation with either liposomes or an artificial polymer, and contain bupivacaine.

Latest News

5 Nov. 2020
PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors
19 Oct. 2020
PainReform Highlights Surgical Advantages of PRF-110
29 Sep. 2020
PainReform Commences Preparations for Pivotal Phase 3 Clinical Trials
10 Sep. 2020
PainReform Announces Closing of $20.0 Million Initial Public Offering
8 Sep. 2020
PainReform Announces Pricing of $20.0 Million Initial Public Offering